Journal Article
Natural products as HMG-CoA reductase inhibitors (statins) for the management of non-communicable diseases
Radwa N. Muhammad; Nora M. Aborehab; Shaza H. Aly; Noha N. Nasr; Merhan O. Hindam; Aya M. Mustafa; Safaa A. Faheem; Mariam H. Fawzy; Mohammed E. Abo-El Fetoh; Ahmed M. El-Dessouki; Mostafa A. Rabie; Riham A. El-Shiekh; Mahmoud E. Youssef
Inflammopharmacology · Vol. 34, Issue 2 · pp. 883-918 · 2026
Abstract
Non-communicable diseases, such as diabetes, cancer, as well as cardiovascular, metabolic, and central nervous system disorders stand for significant global health burden. Statins, as HMG-CoA reductase inhibitors, have emerged as a basis in the management of hypercholesterolemia and the prevention of cardiovascular disorders. In this review, we summarize the role of statins in a variety of pathologies, ranging from their well-recognized effects in cardiovascular disorders, to the newly revealed favorable effects in cancer, eye, autoimmune, kidney, gastrointestinal, bone, and autoimmune disorders. Additionally, the current review explores insights into the potential role of natural products as HMG-CoA reductase inhibitors. Future research should focus on the synergistic effects of natural therapies with synthetic statins to improve health outcomes in populations burdened by non-communicable diseases.